Drug intelligence / Profile preview

BIIX 1

Development stage: Phase 1
Modality: Small Molecules
Administration: Inhalation

Overview

BIIX 1 is an investigational drug that has been studied in early-phase clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy male volunteers. Administered via inhalation, studies have included multiple increasing doses and dose extension evaluations. The inclusion of a methacholine challenge test in one study suggests a potential application or effect related to the respiratory system, possibly in conditions involving airway reactivity.

Targets

CHRM3 (M3)

Beyond the preview

Go deeper on BIIX 1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIIX 1.

Explore the full profile